August 8, 2007
The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in ALS
Funded by: The ALS Association
Principal investigators:
Ming Chan, MD, Principal Investigator, University of Alberta
Sanjay Kalra, MD, Principal Investigator, University of Alberta
Purpose:
The purpose of the study is to investigate the effects of memantine in
ALS patients using functional outcome measures.
ENROLLMENT STATUS: Open
TARGET NUMBER OF PARTICIPANTS: 42
Inclusion Criteria:
- El Escorial Classification of laboratory supported probable, probable,or definite ALS
- Age 18 80 years
- ALS symptoms for no more than 3 years
- FVC greater than or equal to 70% predicted
- Riluzole naïve or have been on a stable dose of Riluzole for at least 2 months.
Exclusion Criteria:
- Presence of significant sensory abnormalities, dementia, other neurologic diseases, uncompensated medical illness and psychiatric illness
- Female patients who are breastfeeding
- Use of concurrent investigational drugs,
- Patient unlikely to comply with study requirements
- Poor adherence to study protocol during run-in phase
CONTACT INFORMATION:
(780) 407-2944
rsekhon@ualberta.ca
University of Alberta ALS Clinic
Edmonton, Alberta, T6G 2B7
Canada
